跳到正文
研踪PaperTrail
← 研踪 PaperTrail

arXiv:2611.10613 · v1

Clinical Evidence-Guided Residual Learning for Medication Recommendation with Dynamic DDI Regularization

首次提交 2026-11-07 17:34
版本更新 2026-11-07 17:34
雷达观测 2026-11-10 11:14
arXiv ↗PDF ↗

摘要

Medication recommendation must combine patient-specific treatment evidence with the interaction structure of a prescription. The central challenge is to determine which evidence supports each medication and how strongly to regularize interactions while preserving predictive quality. We propose EviDrug, a clinical evidence-guided residual learning framework. Its clinical-memory backbone integrates a self-trained visit-aware encoder, training-case memory and one medication-set interaction block to establish a patient-specific prescription. A gated refinement head combines the backbone states with clinical associations and history-conditioned medication identities through bounded logit corrections. Drug-drug interaction (DDI) feedback adapts regularization strength using training-query predictions. Across MIMIC-IV, NWICU and SICdb, EviDrug leads twelve published-method baselines in AP, F1 and Jaccard, improving AP by 2.26, 2.06 and 1.71 percentage points over the strongest comparator. These gains come at lower parameter and runtime costs than MetaDrug. Matched controls demonstrate DDI reductions with stable predictive quality. Code is available at https://github.com/LIZESHENG13/EviDrug.

作者备注:13 pages, 6 figures, 8 tables. Supplementary PDF and detailed result tables are included as ancillary files. Code: https://github.com/LIZESHENG13/EviDrug

AI 论文解读

基于摘要 · 非全文审阅

此版本尚未生成 AI 解读。解读由后台任务生成并按论文版本保存,登录后共享已有结果。

版本差异

目前只观测到一个版本,无法比较变化。之后收录新版本时,会在这里对照标题、作者、分类和摘要。

观测到的版本

相邻记录可能跳过中间版本;首次发现 v2 及以上也会标为版本更新。

v1 · 2026-11-07 17:34 · 最新观测版本

Clinical Evidence-Guided Residual Learning for Medication Recommendation with Dynamic DDI Regularization

Medication recommendation must combine patient-specific treatment evidence with the interaction structure of a prescription. The central challenge is to determine which evidence supports each medication and how strongly to regularize interactions while preserving predictive quality. We propose EviDrug, a clinical evidence-guided residual learning framework. Its clinical-memory backbone integrates a self-trained visit-aware encoder, training-case memory and one medication-set interaction block to establish a patient-specific prescription. A gated refinement head combines the backbone states with clinical associations and history-conditioned medication identities through bounded logit corrections. Drug-drug interaction (DDI) feedback adapts regularization strength using training-query predictions. Across MIMIC-IV, NWICU and SICdb, EviDrug leads twelve published-method baselines in AP, F1 and Jaccard, improving AP by 2.26, 2.06 and 1.71 percentage points over the strongest comparator. These gains come at lower parameter and runtime costs than MetaDrug. Matched controls demonstrate DDI reductions with stable predictive quality. Code is available at https://github.com/LIZESHENG13/EviDrug.

查看此版本解读 →查看此版本原文 ↗